Safety Alerts & Recalls

Search all Safety Alerts & Recalls

Latest Alerts

Recall of GlucoPro Insulin Syringes
Nipro Medical Corporation has issued a nationwide recall of all GlucoPro Insulin Syringes. These recalled syringes may have needles that detach from the syringe. When the needle becomes detached from the syringe during use, it can become stuck in the insulin vial, pushed back into the syringe, or remain in the skin after an injection. No injuries from the recalled syringes have been reported to date. This recall includes all GlucoPro Insulin Syringe product codes and lot numbers with expiration dates before 2011-11 (November 1, 2011), including: Product code JD+01U3008-5C with lot number A08022 Product code JD+01U3013-5C with lot number A08013 or A08017 Product code JD+01U3108-5C with lot number A08013 or A08017 Product code JD+03U3008-5C with lot number C08022 Product code JD+03U3013-5C with lot number C08013 or C08017 Product code JD+03U3108-5C with lot number C08013 or C08017 Product code JD+05U3008-5C with lot number B08022 Product code JD+05U3013-5C with lot number B08013 or B08017 Product code JD+05U3108-5C with lot number B08013 or B08017 Only GlucoPro Insulin Syringes are the subject of the recall. For more information please visit: http://www.fda.gov/Safety/Recalls/ucm198429.htm
Learn More

Recall of GlucoPro Insulin Syringes
Nipro Medical Corporation has issued a nationwide recall of all GlucoPro Insulin Syringes. These recalled syringes may have needles that detach from the syringe. When the needle becomes detached from the syringe during use, it can become stuck in the insulin vial, pushed back into the syringe, or remain in the skin after an injection. No injuries from the recalled syringes have been reported to date. This recall includes all GlucoPro Insulin Syringe product codes and lot numbers with expiration dates before 2011-11 (November 1, 2011), including: Product code JD+01U3008-5C with lot number A08022 Product code JD+01U3013-5C with lot number A08013 or A08017 Product code JD+01U3108-5C with lot number A08013 or A08017 Product code JD+03U3008-5C with lot number C08022 Product code JD+03U3013-5C with lot number C08013 or C08017 Product code JD+03U3108-5C with lot number C08013 or C08017 Product code JD+05U3008-5C with lot number B08022 Product code JD+05U3013-5C with lot number B08013 or B08017 Product code JD+05U3108-5C with lot number B08013 or B08017 Only GlucoPro Insulin Syringes are the subject of the recall. For more information please visit: http://www.fda.gov/Safety/Recalls/ucm198429.htm
Learn More

Date Published Title Drug Source
2010-01-26 Recall of GlucoPro Insulin Syringes Manufacturer
2010-01-26 Recall of GlucoPro Insulin Syringes Manufacturer
2010-01-26 Recall of GlucoPro Insulin Syringes Insulin Glulisine Manufacturer
2010-01-26 Recall of GlucoPro Insulin Syringes NPH Insulin Manufacturer
2010-01-26 Recall of GlucoPro Insulin Syringes Insulin Glargine Manufacturer
2010-01-26 Update on FDA Warning About Counterfeit Alli Orlistat FDA
2010-01-27 Change to Prescribing Information for VELCADE to Include Dosage Adjustment in Liver Impairment Manufacturer
2010-01-28 Additional Recall on Milk of Magnesia: Mint Flavor and Original Flavor FDA
2010-01-28 Recall of Several Lots of Enbrel (etanercept) SureClick Autoinjector, 50 mg/mL Etanercept FDA
2010-01-29 Biogen Idec Announces Monthly Update of Tysabri Monitoring Program Natalizumab Manufacturer
2010-01-29 Serious Liver Disorder Associated with the Use of Didanosine (Marketed as Videx and Videx EC) Didanosine FDA
2010-02-02 Lilly Changes Zyprexa Prescribing Information for Indication for Use in Adolescents (Ages 13 to 17) Fluoxetine with Olanzapine Manufacturer
2010-02-03 Voluntary Recall of Additional Lots of Sanofi Pasteur H1N1 Vaccine Manufacturer
2010-02-05 Risk of Progressive Multifocal Leukoencephalopathy (PML) Increases with the Number of Tysabri (Natalizumab) Infusions Received Natalizumab FDA
2010-02-16 The FDA Requires a Risk Management Program for Erythropoiesis-Stimulating Agents (ESAs) Epoetin Alfa FDA
2010-02-17 Statin Benefits Still Outweigh New Safety Information Atorvastatin MediGuard CRT
2010-02-18 Product Confusion with Maalox Total Relief and Maalox Liquid Products Aluminium Hydroxide with Magnesium Hydroxide FDA
2010-02-18 New Safety Requirements for Long-acting Inhaled Asthma Medications Called Long-Acting Beta-Agonists (LABAs) Formoterol with Budesonide FDA
2010-02-18 Boxed Warning and Other Changes to the EXJADE Prescribing Information Deferasirox Manufacturer
2010-02-19 Recall of Four Lots of ANTIBACTERIAL WASHCLOTHS Containing Benzalkonium Chloride FDA